awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37268998-098459FB-FAC7-4D1C-BADE-3776995D154C
Q37268998-098459FB-FAC7-4D1C-BADE-3776995D154C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37268998-098459FB-FAC7-4D1C-BADE-3776995D154C
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
P2860
Q37268998-098459FB-FAC7-4D1C-BADE-3776995D154C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37268998-098459FB-FAC7-4D1C-BADE-3776995D154C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4bd1781f5caf1dd96ab6d8ec48d4d04e1be9195f
P2860
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.